AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh (ABBV34) Price & Analysis

Q: Is AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh overvalued?

According to Wall Street analysts AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Which hedge fund is a major shareholder of AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh?

Currently, no hedge funds are holding shares in BR:ABBV34

― Followers

ABBV34 Stock Chart & Stats

R$85.13

R$2.86(3.48%)

Jul 28, 2026

―

Day’s Range― - ―

52-Week RangeR$58.81 - R$85.52

Previous CloseN/A

VolumeN/A

Average Volume (3M)2.44K

Market Cap

R$2.33T

Enterprise ValueR$456.58K

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)7479.1

Beta-0.44

Next Earnings

Jul 31, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding1,766,792,800

10 Day Avg. Volume5,801

30 Day Avg. Volume2,435

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh News

AbbVie announces Elahere availability in Singapore

AbbVie (ABBV) announced availability of Elahere in Singapore for the treatment of Platinum-Resistant Ovarian Cancer. Elahere is the...

9h ago

ABBV

AbbVie announces European Commission approval for Rinvoq

AbbVie (ABBV) announced that the European Commission has approved Rinvoq for the treatment of adult and adolescent patients...

9h ago

ABBV

AbbVie price target raised to $300 from $275 at Barclays

Barclays raised the firm’s price target on AbbVie (ABBV) to $300 from $275 and keeps an Overweight rating...

9h ago

ABBV

Genmab, AbbVie provide clarification on Phase 3 EPCORE(R) DLBCL-1 trial

Genmab A/S (GMAB) and AbbVie (ABBV) provided clarification on the primary endpoints from the Phase 3 EPCORE(R) DLBCL-1...

6d ago

ABBV

GMAB

AbbVie price target raised to $282 from $273 at Canaccord

Canaccord raised the firm’s price target on AbbVie (ABBV) to $282 from $273 and keeps a Buy rating...

7d ago

ABBV

AbbVie: Neutral Stance Maintained as Fundamentals Improve and APGE-Driven Rally Leaves Valuation Fair; Price Target Reaffirmed at $244

Analyst Asad Haider from Goldman Sachs maintained a Hold rating on AbbVie and keeping the price target at...

7d ago

ABBV

ABBV34 FAQ

What was AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s price range in the past 12 months?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh lowest stock price was R$58.81 and its highest was R$85.52 in the past 12 months.

What is AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s market cap?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s market cap is R$2.33T.

When is AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s upcoming earnings report date?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s upcoming earnings report date is Jul 31, 2026 which is in 2 days.

How were AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s earnings last quarter?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh released its earnings results on Apr 29, 2026. The company reported R$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by R$0.002.

Is AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh overvalued?

According to Wall Street analysts AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh pay dividends?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh does not currently pay dividends.

What is AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s EPS estimate?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh have?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh has 1,766,792,800 shares outstanding.

What happened to AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s price movement after its last earnings report?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh reported an EPS of R$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.014%.

Which hedge fund is a major shareholder of AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh?

Currently, no hedge funds are holding shares in BR:ABBV34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology